Correction

IMMUNOLOGY. For the four articles (i) “A dual altered peptide ligand down-regulates myasthenogenic T cell responses by upregulating CD25- and CTLA-4-expressing CD4⁺ T cells,” by Miri Paas-Rozner, Michael Sela, and Edna Mozes, which appeared in issue 11, May 27, 2003, of Proc. Natl. Acad. Sci. USA (100, 6676-6681; first published May 12, 2003; 10.1073/pnas.1131898100); (ii) “Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ,” by Rina Aharoni, Basak Kayhan, Raya Eilam, Michael Sela, and Ruth Arnon, which appeared in issue 24, November 25, 2003, of Proc. Natl. Acad. Sci. USA (100, 14157-14162; first published November 12, 2003; 10.1073/pnas.2336171100); (iii) “Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4⁺CD25⁺-regulated events leading to apoptosis,” by Hava Ben-David, Michael Sela, and Edna Mozes, which appeared in issue 6, February 8, 2005, of Proc. Natl. Acad. Sci. USA (102, 2028-2033; first published January 26, 2005; 10.1073/pnas.0409549102); and (iv) “Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4⁺CD25⁺ regulatory cells,” by Badiga Venkata Aruna, Michael Sela, and Edna Mozes, which appeared in issue 29, July 19, 2005, of Proc. Natl. Acad. Sci. USA (102, 10285-10290; first published July 12, 2005; 10.1073/pnas.0504578102), the authors note the following. Michael Sela is on the Board of Directors for Teva Pharmaceutical Industries Ltd. and on the Scientific Advisory Board for DeveloGen. Teva Pharmaceutical Industries Ltd. specializes in the development of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. DeveloGen is a pharmaceutical company focusing on the development of treatments for metabolic disorders.